A major advancement for the healthcare field is that osimertinib has been approved by the U.S. FDA (FDA), which is for the treatment of NSCLC (NSCLC).This approval is a major achievement in the fight against lung cancer, which offers a fresh optimism for patients with the frequent fatal illness.Osimertinib, a precision medicine, specifically inhibits the activity of the EGFR (epidermal growth factor receptor) TK, which is a protein that plays a essential function in the development and dissemination of NSCLC (NSCLC).Osimertinib helps to inhibit or halt the growth of tumor…
